Research Article: Bleeding risk and mortality according to antithrombotic agents’ exposure in cancer-related stroke patients: nationwide population-based cohort study in South Korea
Abstract:
Ischemic stroke with active cancer is thought to have a unique mechanism compared to conventional stroke etiologies. There is no gold standard guideline for secondary prevention in patients with cancer-related stroke, hence, adequate type of antithrombotic agent for treatment is controversial.
Introduction:
Cancer and ischemic stroke are diseases with high morbidity and mortality worldwide [1,2,3]. The association between these two diseases has been reported frequently. Unlike the traditional stroke etiologies, cerebral infarction in patients with cancer is thought to have a different mechanism, and there are many controversies about it [4,5,6]. Thromboembolism is a well-known complication affecting 7–18% of cancer patients; thus, cancer-coagulopathy is considered as a potential etiology of ischemic stroke [7, 8].…
Read more